DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $12.3333.

Several research firms have issued reports on DMAC. TD Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. Cantor Fitzgerald assumed coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating for the company. Cowen started coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $8.31 on Friday. The firm has a market capitalization of $432.76 million, a price-to-earnings ratio of -11.70 and a beta of 1.31. The company’s 50-day moving average is $7.46 and its two-hundred day moving average is $5.97. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg bought 240,352 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were bought at an average price of $7.21 per share, with a total value of $1,732,937.92. Following the completion of the transaction, the insider directly owned 8,375,092 shares in the company, valued at $60,384,413.32. This trade represents a 2.95% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 1,061,277 shares of company stock worth $7,632,627. Company insiders own 7.30% of the company’s stock.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DMAC. Russell Investments Group Ltd. purchased a new position in shares of DiaMedica Therapeutics in the third quarter valued at approximately $27,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in DiaMedica Therapeutics during the 2nd quarter worth approximately $29,000. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 3,710.3% during the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after buying an additional 8,274 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in DiaMedica Therapeutics in the 2nd quarter valued at approximately $49,000. Finally, Invesco Ltd. acquired a new position in shares of DiaMedica Therapeutics in the second quarter worth $54,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.